Cryoport | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 44.23 M

Revenue: As of FY2025 Q3, the actual value is USD 44.23 M, beating the estimate of USD 41.22 M.

EPS: As of FY2025 Q3, the actual value is USD -0.18, beating the estimate of USD -0.2135.

EBIT: As of FY2025 Q3, the actual value is USD -12.81 M.

Life Sciences Services Segment

• Revenue: $24.3 million for the three months ended September 30, 2025, compared to $20.9 million for the same period in 2024, representing a 15.9% increase.
• Cost of Revenue: $12.2 million for the three months ended September 30, 2025, compared to $10.8 million for the same period in 2024, representing a 12.8% increase.
• Gross Margin: 49.7% for the three months ended September 30, 2025, compared to 48.3% for the same period in 2024.

Life Sciences Products Segment

• Revenue: $20.0 million for the three months ended September 30, 2025, compared to $17.4 million for the same period in 2024, representing a 14.9% increase.
• Cost of Revenue: $10.7 million for the three months ended September 30, 2025, compared to $10.1 million for the same period in 2024, representing a 6.4% increase.
• Gross Margin: 46.4% for the three months ended September 30, 2025, compared to 42.1% for the same period in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $9.5 million for the nine months ended September 30, 2025, compared to $10.8 million for the same period in 2024.
• Investing Cash Flow: Net cash provided by investing activities was $250.3 million for the nine months ended September 30, 2025, compared to $173.3 million for the same period in 2024.
• Financing Cash Flow: Net cash used in financing activities was $18.9 million for the nine months ended September 30, 2025, compared to $163.5 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The divestiture of the CRYOPDP business to DHL is expected to enhance Cryoport’s ability to develop its business, particularly in the EMEA and APAC regions, and to provide differentiated and high-value services aligned with the Company’s long-term growth strategy.
• Non-Core Business: The strategic partnership with DHL following the divestiture is anticipated to support Cryoport’s expansion and service differentiation in key international markets.